Novavax Cost Of Revenue from 2010 to 2024

NVAX Stock  USD 9.11  0.09  1.00%   
Novavax Cost Of Revenue yearly trend continues to be fairly stable with very little volatility. Cost Of Revenue is likely to outpace its year average in 2024. During the period from 2010 to 2024, Novavax Cost Of Revenue regression line of annual values had significance of  0.01 and arithmetic mean of  217,887,493. View All Fundamentals
 
Cost Of Revenue  
First Reported
1996-03-31
Previous Quarter
36 M
Current Value
60.6 M
Quarterly Volatility
56.3 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Novavax financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novavax's main balance sheet or income statement drivers, such as Depreciation And Amortization of 43.3 M, Interest Expense of 15.1 M or Selling General Administrative of 499.1 M, as well as many indicators such as Price To Sales Ratio of 0.47, Dividend Yield of 0.0066 or Days Sales Outstanding of 82.31. Novavax financial statements analysis is a perfect complement when working with Novavax Valuation or Volatility modules.
  
Check out the analysis of Novavax Correlation against competitors.
For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.

Latest Novavax's Cost Of Revenue Growth Pattern

Below is the plot of the Cost Of Revenue of Novavax over the last few years. Cost of Revenue is found on Novavax income statement and represents the costs associated with goods and services Novavax provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities. It is Novavax's Cost Of Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novavax's overall financial position and show how it may be relating to other accounts over time.
Cost Of Revenue10 Years Trend
Slightly volatile
   Cost Of Revenue   
       Timeline  

Novavax Cost Of Revenue Regression Statistics

Arithmetic Mean217,887,493
Coefficient Of Variation126.55
Mean Deviation200,385,591
Median162,644,000
Standard Deviation275,741,773
Sample Variance76033.5T
Range902.9M
R-Value0.64
Mean Square Error48390.7T
R-Squared0.41
Significance0.01
Slope39,433,035
Total Sum of Squares1064469.4T

Novavax Cost Of Revenue History

2024361 M
2023343.8 M
2022902.6 M
202112.7 M
2020747 M
2019113.8 M
2018173.8 M

About Novavax Financial Statements

Novavax investors use historical fundamental indicators, such as Novavax's Cost Of Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Novavax. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue343.8 M361 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Novavax Stock Analysis

When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.